Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 51-60 of 406 for multiple

Edit search filters
  1. A Study Of AO-176 As Monotherapy Combinated With Bortezomib And Dexamethasone In Adults With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Idasanutlin, Ixazomib Citrate, And Dexamethasone In Treating Patients With Relapsed Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  3. MMRC Horizon One Adaptive Platform Trial Evaluating Therapies In RRMM

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study Evaluating The Efficacy And Safety Of Cevostamab In Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Dose-Escalation Study Of Cevostamab (BFCR4350A) In Participants With Relapsed Or Refractory Multiple Myeloma (R/R MM)

    Scottsdale/Phoenix, AZ

  6. GPRC5D-directed CAR T Cell Therapy In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Combination Treatment Therapy Approaches For The Treatment Of High-Risk Multiple Myeloma, REACH Trial

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A Study To Determine Recommended Dose, Regimen And Evaluate The Safety And Preliminary Effectiveness Of CC-92480 In Combination With Standard Treatments In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM) And Newly Diagnosed Multiple Myeloma (NDMM)

    Rochester, MN

  9. Belantamab, Lenalidomide, And Daratumumab For Newly-diagnosed Multiple Myeloma

    Rochester, MN

  10. Study Of ORIC-533 In Relapsed Or Refractory Multiple Myeloma

    Rochester, MN

.

Mayo Clinic Footer